Critical Review: Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) & Talphera (NASDAQ:TLPH)

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) and Talphera (NASDAQ:TLPH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Shionogi & Co., Ltd. Unsponsored ADR and Talphera, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shionogi & Co., Ltd. Unsponsored ADR	0	0	0	0	0.00
Talphera	1	0	1	0	2.00

Talphera has a consensus target price of $6.00, suggesting a potential upside of 620.37%. Given Talphera’s stronger consensus rating and higher possible upside, analysts clearly believe Talphera is more favorable than Shionogi & Co., Ltd. Unsponsored ADR.

Profitability

This table compares Shionogi & Co., Ltd. Unsponsored ADR and Talphera’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Shionogi & Co., Ltd. Unsponsored ADR	41.82%	13.70%	12.16%
Talphera	N/A	-126.50%	-61.93%

Earnings and Valuation

This table compares Shionogi & Co., Ltd. Unsponsored ADR and Talphera”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shionogi & Co., Ltd. Unsponsored ADR	$2.88 billion	6.08	$1.12 billion	$0.76	13.54
Talphera	$650,000.00	59.73	-$13.00 million	($0.38)	-2.19

Shionogi & Co., Ltd. Unsponsored ADR has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Shionogi & Co., Ltd. Unsponsored ADR, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

1.9% of Shionogi & Co., Ltd. Unsponsored ADR shares are owned by institutional investors. Comparatively, 37.7% of Talphera shares are owned by institutional investors. 5.7% of Talphera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Shionogi & Co., Ltd. Unsponsored ADR has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Talphera has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

About Talphera

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.